TransCode Therapeutics, Inc. Announces Results of Special Meeting
TransCode Therapeutics (RNAZ), the RNA Oncology Company, announced the results of its Special Meeting held on February 25, 2025, following adjournment from February 4, 2025. Shareholders achieved a quorum and approved two key proposals:
- Proposal One: Approved the issuance of Common Stock upon exercise of Series C and D Warrants, including adjustments to warrant exercise prices, an alternative cashless exercise feature for Series D Warrants, and potential future price adjustments (subject to a $2.4882 floor price)
- Proposal Two: Approved the ability to adjourn the Special Meeting if needed for further proxy solicitation regarding the Issuance Proposal
TransCode Therapeutics (RNAZ), l'azienda di oncologia RNA, ha annunciato i risultati della sua Riunione Straordinaria tenutasi il 25 febbraio 2025, dopo il rinvio del 4 febbraio 2025. Gli azionisti hanno raggiunto il numero legale e hanno approvato due proposte chiave:
- Proposta Uno: Approvata l'emissione di azioni ordinarie a seguito dell'esercizio delle Warrants di Serie C e D, inclusi aggiustamenti ai prezzi di esercizio delle warrants, una funzionalità alternativa di esercizio senza contante per le Warrants di Serie D e potenziali aggiustamenti futuri dei prezzi (soggetti a un prezzo minimo di $2.4882)
- Proposta Due: Approvata la possibilità di rinviare la Riunione Straordinaria se necessario per ulteriori sollecitazioni di deleghe riguardanti la Proposta di Emissione
TransCode Therapeutics (RNAZ), la empresa de oncología de ARN, anunció los resultados de su Junta Especial celebrada el 25 de febrero de 2025, tras el aplazamiento del 4 de febrero de 2025. Los accionistas lograron el quórum y aprobaron dos propuestas clave:
- Propuesta Uno: Aprobada la emisión de acciones ordinarias al ejercer las Warrants de Series C y D, incluidos los ajustes a los precios de ejercicio de las warrants, una característica alternativa de ejercicio sin efectivo para las Warrants de Series D y ajustes de precios futuros potenciales (sujeto a un precio mínimo de $2.4882)
- Propuesta Dos: Aprobada la capacidad de aplazar la Junta Especial si es necesario para una mayor solicitud de poder sobre la Propuesta de Emisión
TransCode Therapeutics (RNAZ), RNA 종양학 회사가 2025년 2월 25일에 열린 특별 회의의 결과를 발표했습니다. 이는 2025년 2월 4일 연기된 후의 회의입니다. 주주들은 정족수를 충족하였고 두 가지 주요 제안을 승인했습니다:
- 제안 1: C 및 D 시리즈 워런트 행사 시 보통주 발행 승인, 워런트 행사 가격 조정, D 시리즈 워런트에 대한 현금 없는 행사 기능, 그리고 잠재적인 미래 가격 조정(최소 가격 $2.4882 적용)
- 제안 2: 발행 제안에 대한 추가 위임 요청을 위해 필요할 경우 특별 회의를 연기할 수 있는 능력 승인
TransCode Therapeutics (RNAZ), la société d'oncologie à base d'ARN, a annoncé les résultats de sa Réunion Spéciale tenue le 25 février 2025, suite à un ajournement du 4 février 2025. Les actionnaires ont atteint le quorum et ont approuvé deux propositions clés :
- Proposition Un: Approbation de l'émission d'actions ordinaires lors de l'exercice des warrants de Série C et D, y compris des ajustements des prix d'exercice des warrants, une fonctionnalité alternative d'exercice sans espèces pour les warrants de Série D, et des ajustements de prix futurs potentiels (sous réserve d'un prix plancher de 2,4882 $)
- Proposition Deux: Approbation de la possibilité d'ajourner la Réunion Spéciale si nécessaire pour une sollicitation de procuration supplémentaire concernant la Proposition d'Émission
TransCode Therapeutics (RNAZ), das RNA-Onkologie-Unternehmen, gab die Ergebnisse seiner Sonderversammlung bekannt, die am 25. Februar 2025 stattfand, nachdem sie am 4. Februar 2025 unterbrochen wurde. Die Aktionäre erreichten das Quorum und genehmigten zwei wichtige Vorschläge:
- Vorschlag Eins: Genehmigung der Ausgabe von Stammaktien bei Ausübung der Series C und D Warrants, einschließlich Anpassungen der Ausübungspreise der Warrants, einer alternativen barlosen Ausübungsfunktion für die Series D Warrants und potenziellen zukünftigen Preisänderungen (unterliegt einem Mindestpreis von $2.4882)
- Vorschlag Zwei: Genehmigung der Möglichkeit, die Sonderversammlung bei Bedarf für weitere Stimmrechtsvertretungen zur Emissionsvorschlag zu vertagen
- Shareholder approval obtained for warrant exercise and pricing flexibility
- Alternative cashless exercise feature added for Series D warrants
- Potential dilution from warrant exercises
- Downward adjustment of warrant exercise prices possible
The presence, by remote communication or by proxy, of the holders of at least one-third of the outstanding shares of capital stock entitled to vote at the meeting were represented at the Special Meeting, constituting a quorum.
- Proposal One was a proposal to approve (i) for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of Common Stock by the Company upon exercise of the Series C Warrants and the Series D Warrants (both as defined in the Special Meeting Proxy Statement), (ii) a series of adjustments to the exercise price of the Warrants and an increase in the underlying Common Stock of the Warrants, (iii) an alternative cashless exercise feature in the Series D Warrants and (iv) an adjustment to the exercise price and number of Warrants upon the Shareholder Approval Date (as defined in the Special Meeting Proxy Statement) and possibly at other times, subject to a floor price of
$2.48 82 - Proposal Two was a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there were insufficient votes for, or otherwise in connection with, the approval of the Issuance Proposal (the "Adjournment Proposal" or "Proposal 2"). Proposal Two was approved by a majority of the votes cast at the Special Meeting.
About TransCode Therapeutics
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
View original content:https://www.prnewswire.com/news-releases/transcode-therapeutics-inc-announces-results-of-special-meeting-302383931.html
SOURCE TransCode Therapeutics, Inc.
FAQ
What proposals were approved at TransCode Therapeutics (RNAZ) Special Meeting on February 25, 2025?
What is the floor price set for RNAZ warrant adjustments in the approved Issuance Proposal?
What changes were approved for RNAZ Series D Warrants in February 2025?
When was the original RNAZ Special Meeting scheduled before adjournment?
